Quick answer
EHL Bio publishes a case example where glucose fell from 300 to 120 mg/dL and HbA1c (NGSP) from 10.8% to 6.3% after stem cell treatment. The numbers are striking but they are single-case data, not a randomised controlled trial. The scientific rationale is that MSCs reduce chronic inflammation and insulin resistance, rather than fully regenerating beta cells.
